Solar Funding II Limited – Annual report and audited financial statements for the year ended 31 October 2025 Solar Funding II Limited hereby announces that the annual report and audited financial statements for the year ended 31 October 2025 are hereby published. Attachment 2025.10.31-Solar Funding II Limited AFR-Signed ...

Core Viewpoint - Bakkt, Inc. has announced a registered direct offering of shares and pre-funded warrants, aiming to raise approximately $48.125 million for working capital and strategic initiatives [1]. Group 1: Offering Details - The offering consists of 3,024,799 shares of Class A common stock and pre-funded warrants for 2,475,201 shares, priced at $8.75 per share and $8.7499 per warrant [1]. - The offering is expected to close on or around March 2, 2026, pending customary closing conditions [1]. - Cohen & Company Capital Markets is acting as the sole placement agent for this offering [2]. Group 2: Regulatory and Compliance Information - The offering is made under a shelf registration statement on Form S-3, effective since July 3, 2025 [3]. - A final prospectus supplement will be filed with the SEC, and the securities are offered only through a written prospectus [3]. Group 3: Company Overview - Bakkt, founded in 2018, focuses on building financial infrastructure for digital assets, including Bitcoin and stablecoin payments [5]. - The company aims to facilitate institutional participation in the digital asset economy, emphasizing security and regulatory compliance [5]. - Bakkt is headquartered in New York, NY [6].

Core Viewpoint - Credicorp Ltd. is set to hold its 2026 Annual General Meeting of Shareholders on March 31, 2026, where the Board of Directors will propose new candidates for election as part of a structured refreshment process aimed at enhancing expertise in technology, AI, and financial governance [1][2]. Board Composition and Nominees - The Board will propose the election of three new directors: María Inés Álvarez (Independent), Juan Paredes Manrique (Independent), and Manuel Romero Valdez (Non-Independent) [3]. - The new nominees are intended to succeed retiring directors Antonio Abruña Puyol, Alexandre Gouvêa, and Patricia Lizárraga Guthertz, while all other current directors will stand for re-election [3][9]. Nomination Process - The nomination process was overseen by the Compensation and Nominations Committee, ensuring compliance with the Company's Bye-laws and Corporate Governance Policies, including independence assessments and conflict-of-interest safeguards [4]. - The Audit Committee will remain composed entirely of independent directors, maintaining robust oversight of financial reporting and risk management [4]. New Director Profiles - **María Inés Álvarez**: A technology executive with over 30 years of experience in AI and cybersecurity, previously at Microsoft, enhancing the Board's oversight of digital transformation [5]. - **Juan Paredes Manrique**: An independent consultant with extensive experience in external audit and regulatory matters, reinforcing financial reporting and compliance oversight [6]. - **Manuel Romero Valdez**: Chairman of Grupo Romero with a background in corporate finance and strategy, contributing to long-term capital allocation and governance [7]. Continuity and Experience - The Board will also propose the re-election of existing directors, including Nuria Aliño Pérez and María Teresa Aranzabal Harreguy, who bring continuity and deep institutional knowledge [8]. - The Board emphasizes maintaining diversity, with women representing one-third of its composition [4]. Dividend Policy Update - The Board approved an update to the Company's dividend policy, maintaining a minimum payout of 25% of consolidated net profits, aligning with regulatory capital considerations [11]. Company Overview - Credicorp is the leading financial services holding company in Peru, with operations in multiple countries and a diversified business portfolio across Universal Banking, Microfinance, Insurance & Pension Funds, and Investment Management & Advisory [12].

Core Insights - Boralex Inc. reported improved financial results for Q4 2025, driven by favorable wind conditions and new project commissioning, although overall annual results declined due to lower short-term electricity contract production [6][7][12]. Financial Results - Q4 2025 power production increased by 18% to 1,800 GWh compared to Q4 2024, while annual production rose by 8% to 6,147 GWh [7][17]. - Revenues from energy sales and feed-in premiums for Q4 2025 reached $241 million, a 6% increase from Q4 2024, while annual revenues decreased by 3% to $796 million [13][17]. - Operating income for Q4 2025 was $68 million, down from $78 million in Q4 2024, and annual operating income decreased to $166 million from $226 million [7][18]. - EBITDA(A) for Q4 2025 was $178 million, up 6% from Q4 2024, while annual EBITDA(A) fell to $552 million from $581 million [7][18]. - Net earnings for Q4 2025 were $26 million, compared to a net loss of $2 million in Q4 2024, while annual net earnings decreased to $33 million from $74 million [7][18]. Development and Construction Activities - Boralex commissioned six new projects in 2025, increasing installed capacity to 3,783 MW, including the Limekiln wind farm in the UK and several battery energy storage systems [6][7]. - Projects totaling 688 MW moved to the secured stage, including solar and battery energy storage projects in the US, Canada, and the UK [7]. - The company secured ministerial approval for the Clashindarroch wind farm extension and a contract for difference for the Sallachy wind farm in the UK [7]. Strategic Outlook - Boralex's 2030 Strategic Plan aims to double installed capacity by 2030 with a focus on growth, diversification, and long-term value creation, supported by $8 billion in investments [19]. - The company continues to expand its portfolio in response to sustained demand for renewable energy, participating in various tender calls in key markets [8][19]. Dividend Declaration - The Board of Directors announced a quarterly dividend of $0.1650 per common share, payable on March 16, 2026 [20]. Corporate Recognition - Boralex received multiple awards in 2025 for its commitment to social responsibility and energy transition, including recognition as one of the best corporate citizens in Canada [9].

Core Viewpoint - Barrick Mining Corporation has released its 2025 Annual Report, Annual Information Form, and Form 40-F, which are now accessible on SEDAR+, EDGAR, and Barrick's website [1]. Group 1: Financial Reports - The 2025 Annual Report and related documents are available for shareholders and the public [1]. - Technical reports for the Pueblo Viejo Mine and Kibali Gold Mine have been filed in compliance with National Instrument 43-101 [2]. Group 2: Company Overview - Barrick is a leading global mining, exploration, and development company with a significant portfolio of gold and copper assets across 17 countries and five continents [4]. - The company is recognized as the largest gold producer in the United States and aims to create long-term value through responsible mining and strong partnerships [4].

Core Viewpoint - TransAlta Corporation will hold an Investor Day on March 23, 2026, to discuss its strategic priorities, long-term plan, financial outlook, and growth opportunities [1]. Group 1: Event Details - The Investor Day will take place in Toronto, starting at 9:00 a.m. ET / 7:00 a.m. MT [2][3]. - The event will be hosted in a hybrid format, allowing both in-person and live webcast attendance [2]. - Registration for the webcast and in-person attendance is available through TransAlta's Investor Centre [2][3]. Group 2: Company Overview - TransAlta is one of Canada's largest publicly traded power generators, providing reliable electricity across Canada, the United States, and Western Australia [4]. - The company has over 100 years of experience in operating and evolving essential energy infrastructure [4]. - TransAlta's diverse technology portfolio and disciplined execution enable it to deliver dependable power while adapting to evolving energy systems [4].

Core Insights - TransAlta Corporation has signed a Memorandum of Understanding (MOU) with Canada Pension Plan Investment Board (CPP Investments) and Brookfield to develop a data centre in Alberta, with TransAlta as the exclusive site and power provider [1][2]. Group 1: MOU and Development Plans - The MOU outlines a phased development framework at the Keephills site in Parkland County, starting with a long-term power purchase agreement for approximately 230 MW and evaluating opportunities for additional development up to 1 GW of load [2][3]. - The Keephills site is strategically positioned, utilizing TransAlta's extensive land, existing infrastructure, and on-site generation capabilities to support large-scale projects [3]. Group 2: Company Background - TransAlta is one of Canada's largest publicly traded power generators, providing reliable electricity across Canada, the United States, and Western Australia for over 100 years [4]. - The company has a diverse technology portfolio and a disciplined approach to energy infrastructure, focusing on meeting current energy needs while preparing for future demands [4].

Core Insights - TransAlta Corporation reported strong performance in 2025, achieving solid free cash flow despite challenges in Alberta power prices and lower merchant production [2][4] - The company announced an eight percent increase in its common share dividend, marking the seventh consecutive annual increase [2][10] Financial Performance - Fourth Quarter 2025 Highlights: - Adjusted EBITDA was $247 million, down from $282 million in Q4 2024 [7] - Free cash flow (FCF) reached $93 million, or $0.31 per share, compared to $46 million, or $0.15 per share in Q4 2024 [7][8] - Net loss attributable to common shareholders was $62 million, or $0.21 per share, compared to a loss of $65 million, or $0.22 per share in Q4 2024 [7][8] - Full Year 2025 Highlights: - Adjusted EBITDA totaled $1,104 million, down from $1,255 million in 2024 [7] - Free cash flow was $514 million, or $1.73 per share, compared to $575 million, or $1.90 per share in 2024 [7][8] - Net loss attributable to common shareholders was $190 million, or $0.64 per share, compared to net earnings of $177 million, or $0.59 per share in 2024 [7][8] Operational Highlights - Achieved operational availability of 90.1% in Q4 2025, up from 87.8% in Q4 2024 [7][8] - Total production for 2025 was 24,521 GWh, compared to 22,811 GWh in 2024 [8] Strategic Developments - The company secured a tolling agreement to convert Centralia Unit 2 to natural gas, extending its operational life [3][21] - TransAlta closed the acquisition of Far North Power Corporation for $95 million, enhancing its capacity in Ontario by 310 MW [14][15] - A memorandum of understanding was signed for data centre development in Alberta, establishing a framework for future growth [12] 2026 Outlook - The company expects adjusted EBITDA for 2026 to be between $950 million and $1,050 million, and free cash flow to be between $350 million and $450 million [10][25] - Anticipated improvements in Alberta power market fundamentals due to expected data centre load growth [4][25]

Core Insights - Treace Medical Concepts, Inc. reported financial results for Q4 and full-year 2025, highlighting a shift in product sales and expectations for future growth [1][3][4]. Financial Performance - Q4 2025 revenue was $62.5 million, a 9% decrease from $68.7 million in Q4 2024, primarily due to a shift towards lower-priced bunion kits [4]. - Gross profit for Q4 2025 was $50.4 million, with a gross margin of 80.6%, slightly down from 80.7% in Q4 2024 [4]. - Total operating expenses in Q4 2025 were $56.3 million, up 1% from $55.7 million in Q4 2024 [5]. - The net loss for Q4 2025 was $(9.4) million, or $(0.15) per share, compared to a net loss of $(0.5) million, or $(0.01) per share, in Q4 2024 [5]. - Adjusted EBITDA for Q4 2025 was $6.2 million, down from $11.1 million in Q4 2024 [5]. Full-Year Results - Full-year 2025 revenue was $212.7 million, a 2% increase from $209.4 million in 2024 [6]. - Gross profit for the full year was $169.8 million, with a gross margin of 79.8%, down from 80.4% in 2024 [6]. - Total operating expenses for 2025 were $223.9 million, slightly down from $224.0 million in 2024 [6]. - The full-year net loss was $(59.0) million, or $(0.93) per share, compared to $(55.7) million, or $(0.90) per share, in 2024 [7]. - Adjusted EBITDA loss for 2025 was $(3.9) million, significantly improved from $(11.0) million in 2024 [7]. Operational Highlights - The company increased its active surgeon base by 202, ending 2025 with 3,337 active surgeons, a 6% increase year-over-year [8]. - The company broadened its global patent portfolio to 135 granted patents and 199 pending applications [8]. Cash Flow and Liquidity - Cash, cash equivalents, and marketable securities totaled $48.4 million as of December 31, 2025 [9]. - The company reduced cash usage by 46% to $27.3 million in 2025 compared to $50.5 million in 2024 [8][9]. 2026 Financial Outlook - The company projects full-year 2026 revenue guidance of $200 million to $212 million, indicating a decline of 6% to 0% compared to 2025 [10]. - Expected Adjusted EBITDA loss for 2026 is projected to be between $(4.0) million and $(6.0) million [10]. - Anticipated reduction in cash usage for 2026 is approximately 50% compared to 2025 [10].

Core Viewpoint - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Dupixent (dupilumab) for treating chronic spontaneous urticaria (CSU) in children aged two to 11 years who have moderate-to-severe symptoms despite treatment with antihistamines [1][2]. Group 1: Product Approval and Clinical Studies - Dupixent's positive opinion is based on data from the LIBERTY-CUPID clinical study program, which includes two phase 3 studies and a single-arm phase 3 study involving children aged two to 11 years [2]. - In the US, a supplemental biologics license application for Dupixent in children aged two to 11 years with CSU has been accepted for review, with a decision expected by April 2026 [3]. Group 2: Disease Background and Treatment Options - Chronic spontaneous urticaria (CSU) is a chronic inflammatory skin disease characterized by debilitating hives and recurring itch, often inadequately controlled by standard antihistamine treatments [5]. - Many patients with CSU experience uncontrolled symptoms despite treatment, leading to a significant impact on their quality of life [5]. Group 3: Dupixent Overview - Dupixent is a fully human monoclonal antibody that inhibits interleukin-4 (IL4) and interleukin-13 (IL13) signaling pathways, which are key drivers of type 2 inflammation [6]. - The drug has received regulatory approvals in over 60 countries for various indications, including CSU, and is currently being used to treat more than 1.4 million patients globally [7]. Group 4: Development and Future Prospects - Dupilumab is being jointly developed by Sanofi and Regeneron, with over 60 clinical studies involving more than 12,000 patients conducted to date [8]. - Sanofi and Regeneron are exploring additional indications for Dupixent, including chronic pruritus of unknown origin and lichen simplex chronicus, which are currently under clinical investigation [9].